Supernus posts Q3 2026 results and nears Indivior merger closing
Supernus Pharmaceuticals reported third‑quarter 2026 revenue of $226.8 million and earnings per share of $0.35. The results came as the company prepared to complete its merger with Indivior, which shareholders approved on October 15. The combined entity is expected to generate about $2.2 billion of pro forma revenue and $125 million of annual cost synergies. The merger is slated to close on November 2, 2026.
Why it matters
The company raised its full‑year 2026 revenue guidance to $887.5 million, indicating stronger sales momentum (the company says). Closing the merger is expected to deliver $125 million of annual cost synergies, which should improve profitability (the company expects).
Key facts
- 1Supernus reported third‑quarter 2026 revenue of $226.8 million. finance.yahoo.com
- 2Supernus reported third‑quarter 2026 earnings per share of $0.35. finance.yahoo.com
- 3The merger of Supernus with Indivior is expected to close on November 2, 2026. finance.yahoo.com
- 4The combined company is projected to generate $125 million in annual cost synergies. finance.yahoo.com
- 5Pro forma net revenue of the combined entity is expected to be approximately $2.2 billion. investing.com
- 6Full‑year 2026 revenue guidance was raised to $887.5 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.